Gene Editing in Primary T Cells


Our promise to you:
Guaranteed product quality, expert customer support.


Gene Editing in Primary T Cells    

Creative Biogene CRISPR/Cas9 Platform provides comprehensive gene editing services for various cell lines, especially for primary T cells. With years of experience, our talented scientists have established an efficient assay to edit genome in T cells by CRISPR/Cas9. At CRISPR/Cas9 PlatformCB, we offer a gene knockout service for customer as well as isolation of primary T cell service. Based on our excellent platform, our staff are focusing on supplying the best services and products.

CRISPR/Cas9 technology has been used as a genome-editing tool for multiple cell lines, such as tumor cell line and embryonic stem cell lines. Primary T cell, as an important class of immune cells system, play an extremely important role in immunity system. It holds great potential for therapeutic applications to engineer genome in primary T cells. However, genome engineering in primary T cells is still a challenge due to low delivery efficiency and limited expression of CRISPR/Cas9 components. In order to overcome these limitations, scientists have done many attempts and finally found an efficient method to overcome them. Nowadays, the widely adopted method is to transfect fully activated T cells with RNPs. Our scientists optimize this method in several details, which improves the efficiency.

Fig 1. Overview of genome editing in primary T cells1

The success of genome editing in primary T cell robustly promotes the development of CAR-T immunotherapy. In CAR-T cells, CAR gene can be delivered to a specific site within the genome by CRISPR/Cas9. Using CRISPR/Cas9 system reduces the risk of gene insertion at incorrect or undesired location. Meanwhile, CRISPR/Cas9 technology is used to knock out endogenous T cell receptor (TCR) and HLA class I (HLA-I) for reducing unwanted graft-versus-host reactivity. In addition to generating of universal CAR-T cells, gene editing also could be used to enhance CAR-T cell function by blocking the expression of T cell inhibitory receptors or signaling molecules, such as PD-1 or CTLA4. Combining CAR-T immunotherapy and CRISPR/Cas9 may improve our chances of success for treating cancer and other genetic disease.

As a global CRISPR/Cas9 service provider, CRISPR/Cas9 PlatformCB provides a genome engineering service for human primary T cells. We will work closely with you and assist you with reliable services and products. 

For more information, please feel free to contact us. We are waiting for your interest projects.

Related Products and Services

Cas9 Protein

Custom Knockout Cell Line Generation

Custom Knockin Cell Line Generation


  1. Judd F. Hultquist, et al. (2017) ‘A CRISPR-Cas9 Genome Engineering Platform in Primary CD4+ T Cells for the Interrogation of HIV Host Factors’, bioRxiv 205500
  2. Yvonne Y. Chen. (2015) ‘Efficient gene Editing in primary Human T cells’, Trends in Immunology 36, 11, P667-669
  3. Theodore L. Roth, et al. (2018) ‘Reprogramming human T cell function and specificity with non-viral genome targeting’, Nature 559, 405-409
For research use only. Not intended for any clinical use.